BC/Yukon Support Blog
“It is rational to offer genetic testing to all French-Canadian women diagnosed recently or in the past with either DCIS (ductal carcinoma in situ) or invasive breast cancer before age 50 or with familial breast cancer above age 50.”
Ghadirian P, Robidoux A, Nassif E, Martin G, Potvin C, Patocskai E, Younan R, Larouche N, Venne A, Zhang S, Royer R, Narod SA.
Clin Genet. 2013 Apr 26. doi: 10.1111/cge.12174. [Epub ahead of print]
OBJECTIVE: To estimate the prevalence of BRCA mutations among early-onset and familial French-Canadian breast cancer patients in a single institution.
METHODS: Study subjects were French-Canadian women with DCIS or invasive breast cancer (incident or prevalent) who were treated and followed at a single breast cancer clinic affiliated with the Research Center of University of Montreal (CRCHUM), who were either aged less than 50 years at diagnosis or who were 50 years or older and with at least two affected first- or second-degree relatives. Subjects were tested for six founder mutations (three in BRCA1 and three in BRCA2).
RESULTS: 1,093 eligible cases were tested. Of these, 56 women (5.1%) were mutation carriers, including 43 BRCA2 carriers and 13 BRCA1 carriers. The prevalence of mutations was 5.3% for unselected women aged 50 and less and was 4.6% for familial cases over age 50. The prevalence of mutations was 3.3% for women with DCIS and was 5.3% for women with invasive cancer.
CONCLUSIONS: It is rational to offer genetic testing to all French-Canadian women diagnosed recently or in the past with either DCIS or invasive breast cancer before age 50 or with familial breast cancer above age 50.